Detalhe da pesquisa
1.
Adjuvant immunotherapy with nivolumab versus observation in completely resected Merkel cell carcinoma (ADMEC-O): disease-free survival results from a randomised, open-label, phase 2 trial.
Lancet
; 402(10404): 798-808, 2023 09 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-37451295
2.
EGFR expression is associated with relapse in a melanoma cohort receiving adjuvant PD-1-based immunotherapy.
J Am Acad Dermatol
; 89(5): 1072-1074, 2023 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-37487833
3.
Features and Long-Term Outcomes of Stage IV Melanoma Patients Achieving Complete Response Under Anti-PD-1-Based Immunotherapy.
Am J Clin Dermatol
; 24(3): 453-467, 2023 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-37142875
4.
Association between Immune-Related Adverse Events and Survival in 319 Stage IV Melanoma Patients Treated with PD-1-Based Immunotherapy: An Approach Based on Clinical Chemistry.
Cancers (Basel)
; 13(23)2021 Dec 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-34885249
5.
An open-label, single-arm, phase II trial of buparlisib in patients with melanoma brain metastases not eligible for surgery or radiosurgery-the BUMPER study.
Neurooncol Adv
; 2(1): vdaa140, 2020.
Artigo
em Inglês
| MEDLINE | ID: mdl-33305271
6.
Primary Resistance to PD-1-Based Immunotherapy-A Study in 319 Patients with Stage IV Melanoma.
Cancers (Basel)
; 12(4)2020 Apr 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-32331243
7.
Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy.
Eur J Cancer
; 60: 190-209, 2016 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-27085692
8.
Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy.
Eur J Cancer
; 60: 210-25, 2016 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-27084345